文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

膝关节骨关节炎:多次关节内注射扩增自体脂肪来源基质细胞或富含血小板血浆的临床和 MRI 结果。

Knee Osteoarthritis: Clinical and MRI Outcomes After Multiple Intra-Articular Injections With Expanded Autologous Adipose-Derived Stromal Cells or Platelet-Rich Plasma.

机构信息

Aspetar Orthopaedic and Sports Medicine Hospital, Doha, Qatar.

出版信息

Cartilage. 2023 Dec;14(4):433-444. doi: 10.1177/19476035231166127. Epub 2023 Jun 22.


DOI:10.1177/19476035231166127
PMID:37350015
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10807730/
Abstract

OBJECTIVE: To directly compare clinical and MRI outcomes of multiple intra-articular injections of adipose-derived stromal cells (ASCs) or platelet-rich plasma (PRP) in patients with knee osteoarthritis (OA). DESIGN: We retrospectively compared 24-month outcomes in (1) 27 patients receiving 3-monthly intra-articular injections with a total of 43.8 million ASCs and (2) 23 patients receiving 3-monthly injections of 3-ml preparation of PRP. All patients had Kellgren-Lawrence grade 1, 2, or 3 knee OA with failed conservative medical therapy. The Numeric Pain Rating Scale (NPRS) scores; Knee injury and Osteoarthritis Outcome Score (KOOS) at baseline, 6, 12, and 24 months after the first injection; and the MRI Osteoarthritis Knee Score (MOAKS) at 12 and 24 months were considered as outcomes. RESULTS: No major complications occurred in any patient. Both groups significantly improved in pain NPRS score and KOOS at 6 months. At 12- and 24-month evaluations, the ASC group significantly decreased scores to a greater degree ( < 0.001) than the PRP group. MOAKS scores indicated a decrease in disease progression in the ASC group. CONCLUSION: Both ASCs and PRP were safe and resulted in clinical improvement in patients with knee OA at 6 months; however, at 12 and 24 months, ASCs outperformed leukocyte-poor PRP in clinical and radiological outcomes.

摘要

目的:直接比较膝关节骨关节炎(OA)患者多次关节内注射脂肪来源基质细胞(ASCs)或富含血小板的血浆(PRP)的临床和 MRI 结果。

设计:我们回顾性比较了 27 名患者在 3 个月内接受共 4380 万 ASC 单次关节内注射和 23 名患者在 3 个月内接受 3 毫升 PRP 制备物注射的 24 个月的结果。所有患者均有 Kellgren-Lawrence 分级 1、2 或 3 级膝 OA,且经保守药物治疗失败。数值疼痛评分量表(NPRS)评分、首次注射后 6、12 和 24 个月的膝关节损伤和骨关节炎结果评分(KOOS)以及 12 和 24 个月的 MRI 骨关节炎膝关节评分(MOAKS)被认为是结果。

结果:任何患者均未发生重大并发症。两组患者的疼痛 NPRS 评分和 KOOS 在 6 个月时均显著改善。在 12 个月和 24 个月评估时,ASC 组的评分下降程度明显大于 PRP 组(<0.001)。MOAKS 评分表明 ASC 组疾病进展程度降低。

结论:ASCs 和 PRP 均安全,可在 6 个月时改善膝 OA 患者的临床症状;然而,在 12 个月和 24 个月时,白细胞减少的 PRP 与 ASC 相比,在临床和影像学结果方面表现不佳。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3551/10807730/3f5d6e64c359/10.1177_19476035231166127-fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3551/10807730/32c1bafec399/10.1177_19476035231166127-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3551/10807730/f0340be192ff/10.1177_19476035231166127-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3551/10807730/24ddeaffcb52/10.1177_19476035231166127-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3551/10807730/b0cf8da6d198/10.1177_19476035231166127-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3551/10807730/83855f4d1b4c/10.1177_19476035231166127-fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3551/10807730/3f5d6e64c359/10.1177_19476035231166127-fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3551/10807730/32c1bafec399/10.1177_19476035231166127-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3551/10807730/f0340be192ff/10.1177_19476035231166127-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3551/10807730/24ddeaffcb52/10.1177_19476035231166127-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3551/10807730/b0cf8da6d198/10.1177_19476035231166127-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3551/10807730/83855f4d1b4c/10.1177_19476035231166127-fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3551/10807730/3f5d6e64c359/10.1177_19476035231166127-fig6.jpg

相似文献

[1]
Knee Osteoarthritis: Clinical and MRI Outcomes After Multiple Intra-Articular Injections With Expanded Autologous Adipose-Derived Stromal Cells or Platelet-Rich Plasma.

Cartilage. 2023-12

[2]
Comparative Clinical Outcomes After Intra-articular Injection With Adipose-Derived Cultured Stem Cells or Noncultured Stromal Vascular Fraction for the Treatment of Knee Osteoarthritis.

Am J Sports Med. 2019-8-2

[3]
Microfragmented Adipose Tissue Versus Platelet-Rich Plasma for the Treatment of Knee Osteoarthritis: A Prospective Randomized Controlled Trial at 2-Year Follow-up.

Am J Sports Med. 2022-9

[4]
Single intra-articular injection with or without intra-osseous injections of platelet-rich plasma in the treatment of osteoarthritis knee: A single-blind, randomized clinical trial.

Injury. 2022-3

[5]
Bone marrow aspirate concentrate versus platelet-rich plasma for treating knee osteoarthritis: a one-year non-randomized retrospective comparative study.

BMC Musculoskelet Disord. 2022-1-3

[6]
Clinical Safety and Effectiveness of Adipose-Derived Stromal Cell vs Stromal Vascular Fraction Injection for Treatment of Knee Osteoarthritis: 2-Year Results of Parallel Single-Arm Trials.

Am J Sports Med. 2022-8

[7]
Comparison of clinical outcome, cartilage turnover, and inflammatory activity following either intra-articular or a combination of intra-articular with intra-osseous platelet-rich plasma injections in osteoarthritis knee: A randomized, clinical trial.

Injury. 2023-2

[8]
Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial.

JAMA. 2021-11-23

[9]
Intra-articular Injection of Autologous Adipose-Derived Stem Cells or Stromal Vascular Fractions: Are They Effective for Patients With Knee Osteoarthritis? A Systematic Review With Meta-analysis of Randomized Controlled Trials.

Am J Sports Med. 2023-3

[10]
Intra-articular injection of culture-expanded mesenchymal stem cells with or without addition of platelet-rich plasma is effective in decreasing pain and symptoms in knee osteoarthritis: a controlled, double-blind clinical trial.

Knee Surg Sports Traumatol Arthrosc. 2019-10-5

引用本文的文献

[1]
Optimal frequency of platelet-rich plasma injections for managing osteoarthritis: A longitudinal study.

Regen Ther. 2025-3-27

[2]
The Combined Use of Triamcinolone and Platelet-Rich Plasma in Equine Metacarpophalangeal Joint Osteoarthritis Treatments: An In Vivo and In Vitro Study.

Animals (Basel). 2024-12-17

[3]
Clinical efficacy of mesenchymal stem cells and platelet-rich plasma in the therapy of osteoarthritis: a meta-analysis.

Am J Transl Res. 2024-9-15

[4]
Injection therapy in professional footballers.

Int Orthop. 2024-11

[5]
Mapping the Research Landscape of Intra-Articular Knee Injections: A Bibliometric Analysis Using the Scopus Database.

Cureus. 2024-7-29

[6]
Intra-Articular Application of Autologous, Fat-Derived Orthobiologics in the Treatment of Knee Osteoarthritis: A Systematic Review.

Cells. 2024-4-25

[7]
Response to Comments by Zhao et al. Regarding "Knee Osteoarthritis: Clinical and MRI Outcomes After Multiple Intra-Articular Injections With Expanded Autologous Adipose-Derived Stromal Cells or Platelet-Rich Plasma".

Cartilage. 2024-6

[8]
Letter to Editor Regarding Article "Knee Osteoarthritis: Clinical and MRI Outcomes After Multiple Intra-Articular Injections With Expanded Autologous Adipose-Derived Stromal Cells or Platelet-Rich Plasma".

Cartilage. 2024-6

本文引用的文献

[1]
Platelet-Rich Plasma Versus Microfragmented Adipose Tissue for Knee Osteoarthritis: A Randomized Controlled Trial.

Orthop J Sports Med. 2022-9-16

[2]
Would you have an injection without knowing its formula? New challenges in platelet-rich plasma therapy.

Int Orthop. 2022-10

[3]
Microfragmented Adipose Tissue Versus Platelet-Rich Plasma for the Treatment of Knee Osteoarthritis: A Prospective Randomized Controlled Trial at 2-Year Follow-up.

Am J Sports Med. 2022-9

[4]
Intra-Articular Injections of Autologous Adipose Tissue or Platelet-Rich Plasma Comparably Improve Clinical and Functional Outcomes in Patients with Knee Osteoarthritis.

Biomedicines. 2022-3-16

[5]
Leukocyte-Rich versus Leukocyte-Poor Platelet-Rich Plasma for the Treatment of Knee Osteoarthritis: A Double-Blind Randomized Trial.

Am J Sports Med. 2022-3

[6]
ADSC-Based Cell Therapies for Musculoskeletal Disorders: A Review of Recent Clinical Trials.

Int J Mol Sci. 2021-9-30

[7]
Which is the most effective one in knee osteoarthritis treatment from mesenchymal stem cells obtained from different sources?-A systematic review with conventional and network meta-analyses of randomized controlled trials.

Ann Transl Med. 2021-3

[8]
Platelet-rich plasma (PRP) in osteoarthritis (OA) knee: Correct dose critical for long term clinical efficacy.

Sci Rep. 2021-2-17

[9]
Promising improvement of chronic lateral elbow tendinopathy by using adipose derived mesenchymal stromal cells: a pilot study.

J Exp Orthop. 2021-1-26

[10]
Patient-Reported Outcomes After Platelet-Rich Plasma, Bone Marrow Aspirate, and Adipose-Derived Mesenchymal Stem Cell Injections for Symptomatic Knee Osteoarthritis.

Clin Med Insights Arthritis Musculoskelet Disord. 2020-7-3

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索